mAbs-PCSK9-Inhibitors. The FOURIER trial showed that therapy with evolocumab a PCSK9 reduced the risk of MACE in PAD patients (HR 0.73, 95% CI 0.59–0.91), it reduced the risk of MALE (HR 0.58, 95% CI 0.38–0.88), so the reduction of LDL seems to reduce the progression of atherothrombosis [73]. The gene discussed is PCSK9; the disease is peripheral arterial disease.